baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Nektar Therapeutics/ US6402681083 /

5/22/2024 10:00:00 PM	Chg. +0.0500	Volume	Bid1:00:05 PM	Ask1:00:05 PM	Market Capitalization	Dividend Y.	P/E Ratio
1.7500USD	+2.94%	1.82 mill. Turnover: 2.96 mill.	1.7000Bid Size: 700	1.7500Ask Size: 3,100	320.77 mill.USD	0.00%	-

GlobeNewswire 5/9 ACELYRIN, INC. Announces Leadership Transition

GlobeNewswire 5/9 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 4/24 Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI...

GlobeNewswire 3/4 Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors

GlobeNewswire 12/29/2023 Chimerix Appoints Lisa Decker to Board of Directors

GlobeNewswire 12/28/2023 Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Myriam J. C...

GlobeNewswire 11/13/2023 Nucleome Therapeutics appoints Dr Stephen Harrison as Chief Scientific Officer

GlobeNewswire 9/15/2023 Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

GlobeNewswire 3/8/2022 Nykode Therapeutics to Present at 2022 American Association for Cancer Research (AACR) Annual Meetin...

GlobeNewswire 3/8/2022 Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the...

GlobeNewswire 2/14/2022 Nykode Therapeutics to Present at SVB Leerink 2022 Global Healthcare Conference

GlobeNewswire 2/11/2022 Nykode Therapeutics announces completion of patient enrollment in its Phase 2 trial of VB10.16 in co...

GlobeNewswire 12/28/2021 Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2...

GlobeNewswire 11/22/2021 Virion Therapeutics, LLC Announces the Appointment of Sue Currie, Ph.D. as Chief Operating Officer

GlobeNewswire 11/15/2021 Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and...

GlobeNewswire 11/3/2021 Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Exe...

GlobeNewswire 10/4/2021 Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors

GlobeNewswire 6/15/2021 Werewolf Therapeutics Appoints Chulani Karunatilake, Ph.D. as Chief Technology Officer

GlobeNewswire 5/12/2021 Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer

GlobeNewswire 4/27/2021 VistaGen Therapeutics Announces Appointment of Joanne Curley, Ph.D. to its Board of Directors

GlobeNewswire 4/15/2021 ImCheck Therapeutics Appoints Dr. Loui Madakamutil as CSO

GlobeNewswire 3/22/2021 Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Developm...

GlobeNewswire 3/15/2021 IGM Biosciences Appoints Lisa Decker, Ph.D., as Chief Business Officer

GlobeNewswire 2/25/2021 Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutic...

GlobeNewswire 1/20/2021 ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTE...

Nektar Therapeutics/ US6402681083 /

If you wish to receive reply to your feedback, please provide your email address.